Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 10,853 matching trials from the live ClinicalTrials.gov search.

Filters: Columbus, Ohio Clear all

Conditions: Skin Structure Infections, Bacterial Skin Diseases, Staphylococcal Skin Infections
Interventions: delafloxacin, tigecycline; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 13
States / cities: Anaheim, California • Hawaiian Gardens, California • Oceanside, California + 9 more

Conditions: Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Interventions: OBX-115; Biological
Lead sponsor: Obsidian Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 13
States / cities: Tucson, Arizona • Los Angeles, California • Stanford, California + 8 more

Conditions: Cardiovascular Disease, Cardiomyopathy, Heart Disease, Myocardial Disease, Myocardial Ischemia
Interventions: Atorvastatin Calcium; Drug
Lead sponsor: Philip Binkley; Other
Eligibility: 18 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: etoposide, pegylated liposomal doxorubicin hydrochloride; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 62
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 49 more

Conditions: Nausea and Vomiting Post-foregut Surgery
Interventions: Reletex, IV ondansetron 4 mg q 6 hours for a total of 4 doses, IV promethazine 25 mg q 6 hours prn, Elixir promethazine 25 mg q 6 hours prn after discharge; Device · Drug
Lead sponsor: Kyle A Perry; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pediatric Acute Myelogenous Leukemia (AML)
Interventions: Decitabine; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 1 Year to 16 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 17
States / cities: Phoenix, Arizona • Madera, California • Aurora, Colorado + 14 more

Conditions: Sarcoma
Interventions: carboplatin, paclitaxel; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 99
States / cities: Birmingham, Alabama • Los Angeles, California • New Britain, Connecticut + 73 more

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Bortezomib, Dexamethasone, Doxil; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma
Interventions: Tipifarnib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 171
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more

Conditions: Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions: Muvalaplin, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 10,450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 159
States / cities: Birmingham, Alabama • Apache Junction, Arizona • Gilbert, Arizona + 129 more

Conditions: Preeclampsia and Eclampsia, Preeclampsia Severe, Gestational Hypertension, Chronic Hypertension in Obstetric Context, Superimposed Pre-Eclampsia, Preeclampsia Mild
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 18
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 13 more

Conditions: Relapsed/Refractory Acute Leukemia
Interventions: Revumenib; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 6 Months and older
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more

Conditions: PARKINSON DISEASE (Disorder)
Interventions: Prescriptive Infusion Algorithm, AB-1005; Procedure · Drug
Lead sponsor: AskBio Inc; Industry
Eligibility: 45 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Cleveland, Ohio • Columbus, Ohio • Pittsburgh, Pennsylvania + 1 more

Conditions: Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Interventions: ALV-100, Placebo; Drug
Lead sponsor: Alveus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Miami, Florida • Columbus, Ohio • San Antonio, Texas

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan; Drug
Lead sponsor: OncoC4, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 23
States / cities: Sacramento, California • Aurora, Colorado • Tampa, Florida + 19 more

Conditions: Metastatic Cancer
Interventions: surgical procedure, radiation therapy, stereotactic radiosurgery; Procedure · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2004
U.S. locations: 240
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 2,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 56
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 34 more

Conditions: Triple Negative Breast Neoplasms
Interventions: Bintrafusp alfa; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Newark, Delaware • Jacksonville, Florida • Silver Spring, Maryland + 12 more

Conditions: Patients Indicated for an ICD
Interventions: ICD Therapy - ICD Lead Registry; Device
Lead sponsor: Biotronik, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,997 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 85
States / cities: Albertville, Alabama • Birmingham, Alabama • Gadsden, Alabama + 82 more

Conditions: HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Laboratory Biomarker Analysis, Lapatinib Ditosylate, Stereotactic Radiosurgery, Whole-Brain Radiotherapy; Other · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 292
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 210 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide, Standard of care; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 180
States / cities: Buena Park, California • Burbank, California • Costa Mesa, California + 144 more

Conditions: Solid Tumor, Breast Cancer, Cancer of Head and Neck
Interventions: RO6874281, Trastuzumab, Cetuximab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 5
States / cities: Tucson, Arizona • La Jolla, California • Greeley, Colorado + 2 more

Conditions: Cystic Fibrosis
Interventions: ELX/TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 52
States / cities: Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 47 more

Conditions: Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Fluorothymidine F-18, Positron Emission Tomography, Veliparib; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 3
States / cities: The Bronx, New York • Columbus, Ohio

Search by objective public record fields.

Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Statin Therapy for Ischemic and Nonischemic Cardiomyopathy

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Reletex Versus Standard of Care Therapy for Post-Operative Nausea Control in Patients Undergoing Foregut Surgery

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer

Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification

Expanded Access Program for Revumenib

Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Radiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases

A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

Long-term Evaluation of the Linox Family ICD Leads Registry (GALAXY)

Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer